PTC Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
PTC Therapeutics, Inc. (PTCT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$33.40 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-06
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$65.05M, a 151.58% decline year-over-year.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $31.65M.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$37.41M.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$16.88M, a 291.17% decline year-over-year.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $57.71M, a 7.92% increase from fiscal 2017.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $53.47M, a 17783.28% increase from fiscal 2016.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $299.00K, a 96.39% decline from fiscal 2015.
- PTC Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $8.27M, a 75.90% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$65.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$33.40M 10-Q · filed 2019-08-06 | -$70.82M derived: sum of 3 quarters · filed 2019-08-06 | -$87.69M derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | $31.65M 10-Q · filed 2019-05-02 | -$5.77M derived: sum of 2 quarters · filed 2019-05-02 | -$22.64M derived: sum of 3 quarters · filed 2019-05-02 | $103.47M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-12-31 | -$37.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$54.29M derived: sum of 2 quarters · filed 2019-03-01 | $71.82M derived: sum of 3 quarters · filed 2019-08-06 | $57.71M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$16.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $109.24M derived: sum of 2 quarters · filed 2019-08-06 | $95.12M 10-Q · filed 2018-11-05 | $65.08M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | $126.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $112.00M 10-Q · filed 2019-08-06 | $81.95M derived: sum of 3 quarters · filed 2019-08-06 | $90.78M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$14.12M 10-Q · filed 2019-05-02 | -$44.16M derived: sum of 2 quarters · filed 2019-05-02 | -$35.34M derived: sum of 3 quarters · filed 2019-05-02 | $43.57M derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | -$30.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$21.22M derived: sum of 2 quarters · filed 2019-03-01 | $57.69M derived: sum of 3 quarters · filed 2019-03-01 | $53.47M 10-K · filed 2019-03-01 |
| 2017-09-30 | $8.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $87.73M derived: sum of 2 quarters · filed 2018-11-05 | $83.52M 10-Q · filed 2018-11-05 | $91.55M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $78.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $74.69M 10-Q · filed 2018-08-07 | $82.72M derived: sum of 3 quarters · filed 2019-03-01 | $97.35M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$4.21M 10-Q · filed 2018-05-09 | $3.82M derived: sum of 2 quarters · filed 2019-03-01 | $18.45M derived: sum of 3 quarters · filed 2019-03-01 | $13.94M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $22.66M derived: sum of 2 quarters · filed 2019-03-01 | $18.16M derived: sum of 3 quarters · filed 2019-03-01 | $299.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | $14.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $10.12M derived: sum of 2 quarters · filed 2017-11-02 | -$7.74M 10-Q · filed 2017-11-02 | -$90.43M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | -$4.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$22.36M 10-Q · filed 2017-08-09 | -$105.05M derived: sum of 3 quarters · filed 2018-03-06 | $6.44M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | -$17.86M 10-Q · filed 2017-05-08 | -$100.55M derived: sum of 2 quarters · filed 2018-03-06 | $10.95M derived: sum of 3 quarters · filed 2018-03-06 | $3.34M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | -$82.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $28.80M derived: sum of 2 quarters · filed 2018-03-06 | $21.20M derived: sum of 3 quarters · filed 2018-03-06 | $8.27M 10-K · filed 2018-03-06 |
| 2015-09-30 | $111.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $103.89M derived: sum of 2 quarters · filed 2016-11-03 | $90.96M 10-Q · filed 2016-11-03 | $87.84M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$7.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$20.53M 10-Q · filed 2016-08-04 | -$23.65M derived: sum of 3 quarters · filed 2017-03-16 | $8.05M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$12.92M 10-Q · filed 2016-05-05 | -$16.05M derived: sum of 2 quarters · filed 2017-03-16 | $15.65M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2014-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $28.58M derived: sum of 2 quarters · filed 2017-03-16 | $34.33M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $31.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $37.46M 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | $5.76M 10-Q · filed 2015-07-31 | |||
| 2013-12-31 | $12.69M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |